This Month’s Focus: Devices
Development of HFA-152a as an environmentally sustainable propellant for pressurized metered dose inhalers
A drive to reduce carbon footprints provides motivation to adopt alternative propellants for pressurized metered dose inhalers (pMDIs). Yet the interests of the patient must be foremost in any approach to change. A number of materials have been considered as potential propellants for pMDIs. HFA-152a is under investigation and, to date, has shown an attractive combination of environmental and formulation performance properties.
General Features
Inhaled administration of drugs to animals in pharmaceutical research
While oral or injected dosing of animals is straightforward, inhaled administration of drugs presents technical and logistical challenges. This article outlines considerations and industry practices for performing non-clinical studies in support of inhaled drug development. Topics include selection of test species, generation of the test atmosphere and its presentation to animals, aerosol characterization, dosimetry and pulmonary deposition of inhaled test materials.
Back Page: Is asthma a risk factor for COVID-19? Answers are evolving and likely to be complex
Surprisingly, a small number of studies have shown that patients with asthma are at no greater risk for COVID-19, however, a more in-depth study has shown that people with non-allergic asthma may indeed be at greater risk while those with allergic asthma may not. This article provides brief highlights of various studies, scientific commentaries and news articles on the topic.
Cross-industry organizations: A 2020 update from the Association of Inhalation Toxicologists (AIT)
The Association of Inhalation Toxicologists (AIT) will mark its 39th anniversary in 2020. The organization published an introductory article in Inhalation in 2017. This article provides an update on the activities of the group during the last three years, along with plans for the future as we begin to emerge from lockdown due to the COVID-19 global pandemic.
December Content
Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part III: Implications of type II error probability
The evolution of nasal drug delivery
Back Page: The AAFA Report: “Asthma Disparities in America: A Roadmap to Reducing Burden on Racial and Ethnic Minorities.”
Cross-Industry Organizations: The DDL Conference: Supporting young scientists and recognizing achievement since 1989
Issue Focuses
January: Reference and Buyer’s Resource
February: Product Development/ Contract Testing
April: Instruments
June: Nasal Delivery/Nebulizers
August: Particle Characterization
October: Devices
December: Quality/Compliance
Vicki Schuman
1155 Northland Drive
St. Paul, MN 55120
651-287-5600
Fax 651-287-5650
vschuman@cscpub.com
Inhalation Article Guidelines
Technical article requirements
The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.
All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner. Also, please avoid discussing product or development costs and do not make cost comparisons.
The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.
We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.
Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.
Editorial board review and production
All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.
Contract Testing
Excipients
